Yan Pijun, Zhang Zhihong, Miao Ying, Xu Yong, Zhu Jianhua, Wan Qin
1Department of Endocrinology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000 China.
2Department of General Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000 China.
Diabetol Metab Syndr. 2020 May 19;12:42. doi: 10.1186/s13098-020-00550-2. eCollection 2020.
Neuregulin 4 (Nrg4) is a novel neurotrophic adipokine associated with the development of diabetic peripheral neuropathy (DPN), however, the pathological mechanism remains poorly understood. The purpose of our study was to investigate the association of circulating Nrg4 with DPN and 25-hydroxy vitamin D [25(OH)D], a multifunctional secosteroid hormone that regulates other neurotrophic factors and adipokines gene expression, and other diabetic vascular complications.
Circulating Nrg4 levels were measured with an ELISA kit in 164 newly diagnosed type 2 diabetes mellitus (nT2DM) patients. The relationship between circulating Nrg4 and DPN and other parameters was analyzed.
Circulating Nrg4 levels were significantly lower in nT2DM patients with DPN than those without, and subjects in the highest quartile of circulating Nrg4 had significantly lower vibration perception threshold (VPT), the prevalence of DPN, the proportion of persons with VPT > 25 V, and significantly higher circulating 25(OH)D (all < 0.01). Moreover, circulating Nrg4 was positively and independently associated with 25(OH)D, and was negatively with VPT (< 0.01 or < 0.05), but showed no associations with the prevalence of peripheral arterial disease, diabetic nephropathy, and diabetic retinopathy (all > 0.05). Additionally,the prevalence of DPN and risk of DPN development were progressively decreased with increasing circulating Nrg4 quartiles, independently of potential confounding factors.
These data demonstrate that decreased levels of circulating Nrg4 might lead to the development of DPN through its close interaction with circulating 25(OH)D not with other diabetic vascular complications. Further prospective studies are needed to identify our findings in these populations.
神经调节蛋白4(Nrg4)是一种新型神经营养性脂肪因子,与糖尿病周围神经病变(DPN)的发生发展相关,但其病理机制仍知之甚少。我们研究的目的是探讨循环Nrg4与DPN以及25-羟基维生素D [25(OH)D](一种调节其他神经营养因子和脂肪因子基因表达的多功能甾醇类激素)及其他糖尿病血管并发症之间的关联。
采用酶联免疫吸附测定试剂盒检测164例新诊断的2型糖尿病(nT2DM)患者的循环Nrg4水平。分析循环Nrg4与DPN及其他参数之间的关系。
合并DPN的nT2DM患者的循环Nrg4水平显著低于未合并DPN者,循环Nrg4处于最高四分位数的受试者的振动觉阈值(VPT)显著更低,DPN患病率、VPT>25 V者的比例显著更低,而循环25(OH)D水平显著更高(均P<0.01)。此外,循环Nrg4与25(OH)D呈正相关且独立相关,与VPT呈负相关(P<0.01或P<0.05),但与外周动脉疾病、糖尿病肾病和糖尿病视网膜病变患病率均无关联(均P>0.05)。此外,随着循环Nrg4四分位数的增加,DPN患病率和发生DPN的风险逐渐降低,且不受潜在混杂因素的影响。
这些数据表明循环Nrg4水平降低可能通过其与循环25(OH)D而非其他糖尿病血管并发症的密切相互作用导致DPN的发生。需要进一步的前瞻性研究来验证我们在这些人群中的发现。